CDK4 and pancreatic neoplasm: In pancreatic cancer, CBX3 downregulates FBP1 expression and promotes glycolysis [41], while the CDK4/6-E2F1 pathway increases MAGED1 expression and promotes FBP1 degradation, and the CDK4/6 inhibitor PD0332991 eliminates the Warburg effect [42].